

Neuroinvasive flavivirus pathogenesis is restricted by host genetic factors in Collaborative Cross mice, independently of Oas1b

Brittany A. Jasperse^{a,*}, Melissa D. Mattocks^{a,*}, Kelsey M. Noll^{a,c}, Martin T. Ferris^b, Mark T. Heise^{a,b}, Helen M. Lazear^{a#}

^aDepartment of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

^bDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

^cPresent address: EpiCypher, Research Triangle Park, NC, USA

*Equal contribution

#Corresponding author

Word count

Abstract: 246

Text: 10,656

ABSTRACT

Powassan virus (POWV) is an emerging tick-borne flavivirus that causes neuroinvasive disease, including encephalitis, meningitis, and paralysis. Similar to other neuroinvasive flaviviruses, such as West Nile virus (WNV) and Japanese encephalitis virus (JEV), POWV disease presentation is heterogeneous, and the factors influencing disease outcome are not fully understood. We used Collaborative Cross (CC) mice to assess the impact of host genetic factors on POWV pathogenesis. We infected a panel of *Oas1b*-null CC lines with POWV and observed a range of susceptibility phenotypes, indicating that host factors other than the well-characterized flavivirus restriction factor *Oas1b* modulate POWV pathogenesis in CC mice. Among *Oas1b*-null CC lines, we identified multiple highly susceptible lines (0% survival), including CC071, and a single resistant line (78% survival), CC045. Susceptibility phenotypes generally were concordant among neuroinvasive flaviviruses, although we identified one line, CC006, that was resistant specifically to JEV, suggesting that both pan-flavivirus and virus-specific mechanisms contribute to susceptibility phenotypes in CC mice. We found that POWV replicated to higher titers in bone marrow-derived macrophages from CC071 mice compared to CC045 mice, suggesting that resistance could result from cell-intrinsic restriction of viral replication. Although serum viral loads at 2 days post-infection were equivalent between CC071 and CC045 mice, clearance of POWV from the serum was significantly slower in CC071 mice. Furthermore, CC045 mice had significantly lower viral loads in the brain at 7 days post-infection compared to CC071 mice, suggesting that reduced CNS infection contributes to the resistant phenotype of CC045 mice.

IMPORTANCE

Neuroinvasive flaviviruses, such as WNV, JEV, and POWV, are transmitted to humans by mosquitoes or ticks, can cause neurologic disease, such as encephalitis, meningitis, and paralysis, and can result in death or long-term sequelae. Although potentially severe, neuroinvasive disease is a rare outcome of flavivirus infection. The factors that determine whether someone develops severe disease after flavivirus infection are not fully understood, but host genetic differences in polymorphic antiviral response genes likely contribute to disease outcome. We evaluated a panel of genetically diverse mice and identified lines with distinct outcomes following infection with POWV. We found that resistance to POWV pathogenesis corresponded to reduced viral replication in macrophages, more rapid clearance of virus in peripheral tissues, and reduced viral infection in the brain. These susceptible and resistant mouse lines will provide a system for investigating the pathogenic mechanisms of POWV and identifying polymorphic host genes that contribute to resistance.

INTRODUCTION

Neuroinvasive flaviviruses such as West Nile virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV), tick-borne encephalitis virus (TBEV), and Powassan virus (POWV) are transmitted to humans by mosquitoes or ticks and can spread from the circulation into the central nervous system (CNS) (1, 2). Flavivirus infections exhibit a heterogenous presentation, with ~80% of infections being asymptomatic and ~20% presenting with febrile symptoms. A subset of individuals with symptomatic WNV, JEV, SLEV, TBEV, or POWV infection progress to severe, neuroinvasive disease (e.g., encephalitis, meningitis, or paralysis), which can be fatal or lead to long-term cognitive and functional sequelae. Neurologic disease can result from direct viral infection of neurons and also from the inflammatory response triggered by a viral infection of the CNS. However, the factors influencing susceptibility to severe neuroinvasive disease remain incompletely understood.

POWV is an emerging tick-borne flavivirus within the tick-borne encephalitis serocomplex that is transmitted by the same *Ixodes* ticks that transmit Lyme disease (3). POWV is the only tick-borne flavivirus found in North America. Like other tick-borne diseases, the incidence of POWV infection is increasing (4). POWV was first isolated from the brain of a young boy who died of encephalitis in 1958 in Powassan, Ontario, Canada (5). Forty years later, a virus sharing 94% amino acid identity with POWV was isolated from a deer tick (*Ixodes scapularis*), and was named deer tick virus (DTV) (6, 7). POWV circulates as two distinct but serologically indistinguishable genotypes: Lineage I containing the prototype POWV, and Lineage II, containing DTV (6-8). Infection with POWV can have devastating impacts, as approximately 10% of reported encephalitic

cases of POWV are fatal, and over 50% of survivors experience long-term cognitive and functional sequelae (9).

Flavivirus infection in humans is characterized by significant variation in disease severity, suggesting that host genetic factors impact the probability and outcome of neuroinvasive disease (10-16). Host genes related to the antiviral immune response have been associated with the outcome of flavivirus infection in humans (16). For example, polymorphisms in the dsRNA sensor OAS1 and the chemokine receptor CCR5 are associated with WNV and TBEV infection, symptomatic presentation, and neuroinvasive disease (10, 14, 17, 18). Flavivirus resistance is one of the earliest examples of a genetic determinant of pathogen susceptibility defined in mice. In the 1930s, resistance to flavivirus disease was shown to be inherited in mice (19) and in the 2000s, resistance was mapped to the 2'-5' oligoadenylate synthetase 1b (*Oas1b*) gene (20, 21). The antiviral activity of *Oas1b* restricts all flaviviruses tested and appears to act exclusively against flaviviruses. Genetic resistance to tick-borne flavivirus disease was demonstrated in the 1930s by selective breeding of mouse lines that were either resistant or susceptible to TBEV and louping ill virus (22, 23) and similar studies demonstrated differential susceptibility to the mosquito-borne flaviviruses St. Louis encephalitis virus and yellow fever virus (24-28).

The Collaborative Cross (CC) is a mouse genetic reference population of recombinant inbred lines. These lines were generated by crossing eight founder strains that represent three wild-derived and five classical laboratory mouse lines and then independently inbreeding each family deriving from one of these 8-founder funnels (29, 30). The CC captures the genetic diversity of laboratory mice, roughly on par with levels

of common human genetic variation, in a reproducible manner, since each of the 63 lines has a known and fixed genome, providing a valuable tool for mapping complex traits (29-33). As such, the CC enables the identification and study of polymorphic host genes underlying complex phenotypes including the immune response to viral infection (29-35). Further, since each line is inbred, the CC can be used to facilitate the study of phenotypes that are diverse and dynamic through time (such as the response to infection) in a reproducible manner.

Common laboratory mouse lines (including CC founder lines C57BL/6, A/J, 129, NOD, and NZO) have truncated *Oas1b* alleles that lack 30% of the C terminal sequence due to a premature stop codon, whereas wild-derived lines (CC founder lines WSB, PWK, and CAST) each have unique full-length *Oas1b* alleles, meaning that CC lines carry either a full-length or truncated allele of *Oas1b*. Previous studies using F1 hybrids of CC mice to define genetic determinants of WNV pathogenesis found via genetic mapping that *Oas1b* had a major impact on WNV disease outcome (36, 37). However, the mechanism by which *Oas1b* restricts flavivirus infection remains unclear, since both full-length and truncated *Oas1b* proteins lack synthetase activity (38, 39), although full-length *Oas1b* does inhibit *Oas1a* synthetase activity and reduces 2'-5' linked oligoadenylate production (38).

In this study, we used CC mice to investigate the effect of host genetics on disease outcome following neuroinvasive flavivirus infection. We found that a panel of *Oas1b*^{null} CC lines had a range of susceptibility phenotypes following POWV infection and we used susceptible and resistant lines to investigate mechanisms of POWV pathogenesis. We found that resistance to POWV pathogenesis corresponded to reduced viral replication in

macrophages, more rapid clearance of virus in peripheral tissues, and reduced viral infection in the brain. These findings reveal diverse pathologic outcomes of POWV infection in CC mice and suggest that rapid clearance of POWV in the periphery contributes to reduced neuroinvasion and resistance to lethality. These susceptible and resistant mouse lines will provide a system for investigating the pathogenic mechanisms of POWV and identifying polymorphic host genes that contribute to resistance.

RESULTS

***Oas1b* restricts pathogenesis of neuroinvasive flaviviruses.** To assess the effect of *Oas1b* on neuroinvasive flavivirus pathogenesis in CC mice, we infected three strains of mice: wild-type C57BL/6J (non-functional *Oas1b* allele); CC019 (functional *Oas1b* allele derived from the WSB founder strain), and an *Oas1b*^{del} line on a CC019 background generated by CRISPR/Cas-9 gene editing (see Methods). We infected 5-6-week-old mice with 100 FFU of POWV (strains LB or DTV Spooner), WNV, or JEV and monitored survival for 21 days (Fig. 1A-D). As expected, CC019 mice were resistant to all three viruses, consistent with a strong effect of *Oas1b* on susceptibility to neuroinvasive flaviviruses. We found that CC019-*Oas1b*^{del} mice were susceptible to POWV LB, POWV DTV, WNV, and JEV (80%, 73%, 75% and 60% lethality, respectively). To determine whether genetic determinants of susceptibility in mice corresponded to differences in viral replication, we performed multi-step growth curves in primary mouse embryo fibroblasts (MEFs). We generated MEFs from C57BL/6J, CC019, and CC019-*Oas1b*^{del} mice, infected with POWV or WNV at an MOI of 0.1, and measured viral titers in the culture




Figure 1. *Oas1b* restricts pathogenesis of diverse neuroinvasive flaviviruses. A-D. Five to six-week-old male and female CC019, CC019-*Oas1b*^{del}, or C57BL/6J mice were infected with 100 FFU of POWV strain LB (A), POWV DTV strain Spooner (B), WNV strain NY2000 (C), or JEV strain Nakayama (D) by subcutaneous inoculation in the footpad and lethality was monitored for 21 days. Data are combined from 4-5 experiments per virus. E-F. Mouse embryo fibroblasts (MEFs) were harvested from the indicated mouse lines for multistep growth curve analysis. MEFs were infected at an MOI of 0.01 with POWV strain LB (E) or WNV strain NY2000 (F). Supernatants were collected at 4, 24, 48, or 72 hours post-infection and titered by focus-forming assay on Vero cells. Results shown are the mean \pm SEM of 2-3 independent experiments performed in duplicate or triplicate. Asterisks represent statistical significance (* p<0.05, ** p<0.01, *** p<0.001) by two-way ANOVA compared to CC019-*Oas1b*^{del}. G-H. Nine to twelve-week-old C57BL/6J wild-type or *Oas1g*^{-/-} male and female mice were infected with 100 FFU of POWV strain MB5/12 (G) or WNV strain NY2000 (H) by subcutaneous inoculation in the footpad and lethality was monitored for 21 days.

supernatant over 72 hrs (Fig. 1E-F). POWV replication was significantly higher in MEFs derived from C57BL/6J mice compared to CC019-*Oas1b*^{del} mice starting at 24 hpi (Fig. 1E), with a maximum difference of 8-fold at 48 hpi; WNV-infected MEFs were only significantly different at 72 hpi (4-fold) (Fig. 1F). POWV and WNV replication in CC019-*Oas1b*^{del} MEFs were only modestly increased compared to CC019 MEFs (2- and 3-fold, respectively), and only at 48 hpi. Altogether these results suggest that non-*Oas1b* genetic factors are responsible for the differences in viral replication in MEFs.

Humans have four paralogous OAS genes: *OAS1*, *OAS2*, *OAS3*, and *OASL*. Mice, however, have single copies of *Oas2* and *Oas3*, two copies of *OasL*, and eight copies of *Oas1* (*Oas1a*-*Oas1h*) (39). To determine whether other *Oas1* paralogs play a similar role in restricting flavivirus pathogenesis as *Oas1b*, we infected 9 to 12-week-old *Oas1g*^{-/-} mice (C57BL/6N background) or wild-type mice (C57BL/6J background) with POWV strain MB5/12 or WNV and monitored lethality for 21 days. These older mice were more resistant to POWV and WNV pathogenesis compared to the 5- to 6-week-old mice used in the previous experiments, but we found no significant difference in survival for *Oas1g*^{-/-} mice compared to wild-type (Fig. 1G-H), suggesting the function of *Oas1b* as a flavivirus restriction factor is not conserved among all *Oas1* paralogs.

***Oas1b*-null Collaborative Cross lines exhibit a range of susceptibility phenotypes to neuroinvasive flaviviruses.** To investigate the role of host genetic factors outside of the well-known flavivirus restriction factor *Oas1b*, we infected mice from a panel of 16 CC strains (9 to 12-week-old mice, all lines possessing *Oas1b*^{null} alleles), as well as CC019-*Oas1b*^{del} mice, with POWV strain LB and monitored lethality for 21 days (Fig. 2 and Table 1). As expected, most lines were highly susceptible to POWV (100% lethality in 11 of 17 CC lines). However, we identified one





Figure 2. Host factors influence POWV pathogenesis across *Oas1b*-null Collaborative Cross mouse lines. Nine to twelve-week-old male and female mice were infected with 100 FFU of POWV (strain LB) by subcutaneous inoculation in the footpad and lethality was monitored for 21 days. Lines are ordered by percent survival and mean time to death. N=34 C67BL/6 mice, 18 CC019-*Oas1b*^{del} mice, and 6-7 mice for other lines. Data are combined from 9 experiments.

resistant line (CC045, 0% lethality), and five lines with intermediate susceptibility (CC001, CC027, CC043, CC057, CC062, 50-83% lethality).

To validate the phenotypes observed with POWV strain LB, we infected a subset of the *Oas1b*^{null} CC lines with POWV strain MB5/12, WNV strain NY2000, JEV strain Nakayama, or St. Louis encephalitis virus (SLEV) strain GHA-3 and monitored lethality for 21 days (Fig. 3A-D). CC071 mice were highly susceptible to all viruses tested, with 100% lethality observed after infection with POWV MB5/12 (Fig. 3A) or WNV (Fig. 3B), 91% lethality in JEV-infected mice (Fig. 3C). CC071 mice exhibited 57% lethality after SLEV infection, which was remarkable as C57BL/6J and CC019-*Oas1b*^{del} mice exhibited no lethality after SLEV infection (Fig. 3D). Furthermore, CC045 mice, which were the most resistant CC line to POWV LB (100% survival, Fig. 2), also were relatively resistant to POWV MB5/12 (78% survival, Fig. 3A), WNV (50% survival, Fig. 3B), and JEV (50%



survival, Fig. 3C). Thus, most susceptibility phenotypes were concordant among POWV, WNV, and JEV. However, some lines exhibited virus-specific susceptibility. CC006 mice were highly susceptible to WNV (100% lethality, Fig. 3B), intermediately susceptible to POWV MB5/12 (56% lethality, Fig. 3A), yet were the most resistant CC line to JEV (37% lethality, Fig. 3C). This suggests that there are both pan-flavivirus and virus-specific mechanisms that control susceptibility to neuroinvasive flaviviruses. We also evaluated CC lines with functional *Oas1b* alleles (CC003, WSB allele; CC004, PWK allele; and CC030, WSB allele). As expected, these mice were resistant to POWV MB5/12 infection (0% lethality, Fig. 3E), further supporting that functional *Oas1b* alleles derived from different CC founder lines restrict neuroinvasive flavivirus pathogenesis in CC mice.

Susceptibility of Collaborative Cross lines to neuroinvasive flavivirus pathogenesis does not correlate with early viremia levels. To uncover the pathogenic mechanisms behind the differences in flavivirus susceptibility among *Oas1b*^{null} CC lines, we investigated whether resistance to lethality corresponded with decreased viremia. We measured viral loads in the serum by quantitative reverse transcription-PCR (qRT-PCR) in serum collected 2 dpi from *Oas1b*^{null} CC lines (CC045, CC057, CC006, CC019-*Oas1b*^{-/-}, CC015, and CC071) infected with POWV, WNV, or JEV (Fig. 4). Surprisingly, we found no concordance between mean viremia (Fig. 4A, C, D) and susceptibility (Fig. 3A-C) among the *Oas1b*^{null} CC lines tested. Furthermore, viral loads in the serum were similar between *Oas1b*^{null} CC mice (Fig. 4A) and *Oas1b*^{+/+} CC mice (Fig. 4B). Moreover, within CC lines, there was no difference in viremia between mice that survived (open symbols) compared to mice that succumbed to infection (closed symbols). These data suggest that




Figure 4. Serum viral loads at 2 dpi do not correlate with susceptibility to neuroinvasive flaviviruses. Nine to twelve-week-old male and female mice were infected with 100 FFU of POWV (A and B), WNV (C), or JEV (D) by subcutaneous inoculation in the footpad. Mice were bled 2 dpi and viremia was assessed by qRT-PCR. Asterisks represent statistical significance (* p<0.05, *** p<0.001) by one-way ANOVA compared to CC045 (panels A, C, and D). CC lines in A, C, and D are all *Oas1b*-null; CC lines in B are *Oas1b*+/. Open symbols denote surviving mice.

controlling viremia at 2 dpi is not the mechanism of resistance to flavivirus pathogenesis in these CC lines.

Resistance to neuroinvasive flavivirus pathogenesis correlates with reduced replication in macrophages. To evaluate whether resistance to POWV disease corresponds with cell-intrinsic restriction of viral replication, we generated bone marrow-derived macrophages (BMDM) from CC mice and performed multi-step growth curves with POWV and WNV (Fig. 5). BMDMs from CC071 and CC015 mice produced




Figure 5. Susceptibility to flavivirus disease is concordant with restriction of viral replication in macrophages ex vivo. Bone marrow-derived macrophages (BMDM) were harvested from CC mice (CC045, CC071, and CC015) for multistep growth curve analysis. BMDMs were infected at an MOI of 0.01 with POWV (A) or WNV (B). Supernatants were collected at 4, 24, 48, or 72 hours post-infection and titered by focus-forming assay on Vero cells. Results shown are the mean \pm SEM of 2-3 independent experiments performed in duplicate or triplicate. Asterisks represent statistical significance (* $p < 0.05$, *** $p < 0.001$) by two-way ANOVA compared to CC045.

concordant with the increased susceptibility of CC071 and CC015 mice to POWV infection (Fig. 3A). Similarly, BMDMs from CC015 mice exhibited enhanced WNV replication at 24 and 48 hpi, and CC071-derived BMDMs had significantly higher viral titers at 24 hpi, compared to BMDMs from CC045 mice (18-fold and 9-fold higher at 24 hpi) (Fig. 5B). Thus, resistance to flavivirus disease in CC mice could result from cell-intrinsic restriction of viral replication in macrophages, a key cellular target of flaviviruses *in vivo*.

Resistance to POWV pathogenesis correlates with rapid clearance of peripheral infection and lower CNS viral loads. Although we found no difference in serum viral loads at 2 dpi between susceptible and resistant CC lines (Fig. 4), susceptibility to neuroinvasive flaviviruses could be driven by serum viral loads at later time points, or by viral loads in the CNS, independent of viremia. To further investigate the pathogenic mechanisms of POWV infection, we infected CC lines identified as susceptible (CC071)

and resistant (CC045) and measured viral loads in serum, spleen, and brain at 3 and 7 dpi. CC071 mice exhibited high viremia at 3 dpi (mean 7.9 log₁₀ copies/ml of serum) and POWV RNA was detected in the serum of all 8 CC071 mice harvested at 7 dpi (Fig. 6A). However, 2 of 5 CC045 mice had cleared POWV from the serum by 3 dpi, and viremia was low in the remaining CC045 mice (maximum 5.7 log₁₀ copies/ml of serum), and




Figure 6. Reduced CNS viral loads correlate with POWV resistance. Nine to twelve-week-old male and female CC071 (susceptible) and CC045 (resistant) mice were infected with 100 FFU of POWV (strain MB5/12) by subcutaneous inoculation in the footpad. A-D. At the indicated time points, mice were perfused and tissues were harvested. A. Mice were bled by cardiac puncture prior to perfusion and viremia was assessed by qRT-PCR. B-D. Spleen, brain, and spinal cord homogenates were titrated by plaque assay on Vero cells. E-F. Mice were serially bled 2, 3, and 4 dpi and viremia was assessed by qRT-PCR. Asterisks represent statistical significance (* $p < 0.05$, *** $p < 0.001$) by two-way ANOVA.

253 POWV RNA was not detected in the serum of any of the 5 CC045 mice harvested at 7
254 dpi (Fig. 6A). This suggests that while viral loads in the serum at 2 dpi were equivalent
255 between susceptible (CC071) and resistant (CC045) lines (Fig. 4A), clearance of POWV
256 from the serum was faster in CC045 mice. Despite a >350-fold difference in serum viral
257 loads at 3 dpi between CC071 and CC045 mice, we found no significant difference in
258 spleen viral loads at 3 dpi (Fig. 6B). In contrast, by 7 dpi, all CC045 mice had cleared
259 POWV from the spleen, while CC071 mice had viral loads in the spleen similar to those
260 observed at 3 dpi (Fig. 6B), concordant with the sustained viremia in CC071 mice through
261 7 dpi (Fig. 6A). We also assessed viral loads in the CNS and found that POWV was
262 undetectable in the brains of CC071 and CC045 mice at 3 dpi, but by 7 dpi, all CC071
263 mice had high viral loads in the brain (mean 6.3 Log₁₀ PFU/ml) (Fig. 6C). Interestingly,
264 while 4 of 6 CC045 mice had undetectable viral loads in the brain at 7 dpi, the remaining
265 2 mice had brain viral loads similar to CC071 mice (maximum 6.3 log₁₀ PFU/ml) (Fig. 6C).
266 The observation that 33% of CC045 mice had detectable virus in the brain at 7 dpi (Fig.
267 6C) is concordant with our earlier observation that CC045 mice had 22% lethality to
268 POWV strain MB5/12 (Fig. 3A). POWV was undetectable in the spinal cords of CC071
269 mice at 3 dpi, but by 7 dpi, 2 of 9 CC071 mice had high viral loads in the spinal cord
270 (maximum 7.8 log₁₀ PFU/ml) (Fig. 6D). Interestingly, the 2 CC071 mice that had high viral
271 loads in the spinal cord also had the highest viral loads in the brain at 7 dpi, suggesting
272 the presence of POWV in the spinal cord is due to viral spread within the CNS rather than
273 separate stochastic breaches of the blood-brain barrier (BBB). Further, POWV was not
274 detected in spinal cords from CC045 mice at 3 or 7 dpi (Fig. 6D). Altogether, these data

suggest the mechanism of resistance to POWV infection in CC045 mice is the prevention of neuroinvasion.

To further investigate differences in the rate of clearance of POWV from the periphery in susceptible and resistant mice, we infected CC071 and CC045 mice and performed serial measurements of viral loads in the serum at 2, 3, and 4 dpi to analyze the kinetics of viremia in individual mice. Consistent with our previous experiments, we found that CC071 mice had high viral loads at 2 dpi (mean 6.5 log₁₀ copies/ml), which peaked at 3 dpi (mean 7.5 log₁₀ copies/ml), and remained high in 7 of 8 mice at 4 dpi (mean 6.5 log₁₀ copies/ml) (Fig. 6D). While CC045 mice had high viral loads in the serum at 2 dpi (mean 5.7 Log₁₀ copies/ml), 6 of 8 mice had undetectable viremia at 3 dpi, and all mice had cleared by 4 dpi (Fig. 6E). The viremia kinetics observed in individual CC045 and CC071 mice (Fig. 6D-E) are concordant with our earlier observation in terminally-bled mice that CC045 mice clear POWV from the periphery more rapidly than CC071 mice (Fig. 6A). Altogether, these data support a model of POWV pathogenesis in which rapid clearance of viremia reduces the likelihood of virus breaching the BBB and accessing the CNS, where viral infection results in mortality.

DISCUSSION

In this study, we investigated the effect of host genetics on disease outcome following neuroinvasive flavivirus infection. We found that a panel of *Oas1b*^{null} CC lines had a range of susceptibility phenotypes following POWV infection, indicating that polymorphic host genes other than *Oas1b* contribute to disease outcome after POWV infection. We identified *Oas1b*^{null} CC lines that are susceptible (100% lethality) or resistant

(<25% lethality) to POWV and used these lines to investigate mechanisms of POWV pathogenesis. We observed reduced POWV and WNV replication in primary macrophages derived from resistant mice, suggesting resistance to flavivirus disease in CC mice could result from cell-intrinsic restriction of viral replication in macrophages. We found no differences in POWV viremia between susceptible and resistant CC mice at 2 dpi but found that resistant mice cleared POWV from the periphery rapidly whereas susceptible mice had high viremia throughout the infection. Further, we observed significant differences in viral loads in the brains of susceptible and resistant CC mice following POWV infection. These findings reveal diverse pathologic outcomes of POWV infection in CC mice and suggest that rapid clearance of POWV in the periphery contributes to reduced neuroinvasion and protection from lethality.

Neuroinvasive flaviviruses, such as WNV, JEV, and POWV, can cause neurologic disease, such as encephalitis, meningitis, and paralysis, and can result in death or long-term cognitive and functional sequelae (1, 2, 40). JEV is the most prevalent cause of viral encephalitis worldwide, causing an estimated 68,000 cases and >10,000 deaths annually throughout east and southeast Asia, even though a vaccine is available (41, 42). In 2022, local transmission of JEV was detected in Australia for the first time since 1995 and ultimately led to dozens of reported JEV cases within Australia (43). In North America, West Nile virus (WNV) is the most common cause of viral encephalitis, with 1,855 cases of West Nile neuroinvasive disease reported to the CDC in 2021 and a total of 25,849 US cases since 1999 when the virus was introduced to North America (44). While JEV and WNV are transmitted to humans by mosquitoes, TBEV and POWV are transmitted by ticks. TBEV causes >10,000 cases of encephalitis annually in Europe and Asia despite

the availability of a vaccine (45, 46). POWV is the only tick-borne flavivirus found in North America and like other tick-borne diseases, the incidence of POWV infection is increasing (4). Given the clinical importance of endemic neuroinvasive flaviviruses, as well as the potential for related flaviviruses such as Usutu virus (USUV) to emerge as new human pathogens (47, 48), it is important to understand the factors that lead to severe clinical outcomes after infection with these viruses.

Neurotropic viruses, including neuroinvasive flaviviruses, can cause disease by direct damage to infected neurons, as well as by stimulating pathogenic inflammatory responses (49-52). The pathogenic mechanisms of neuroinvasive flaviviruses have been studied extensively in mice, which recapitulate key features of human disease such as neuronal infection, immune infiltration into the CNS, paralysis, encephalitis, and cognitive loss. Much of this work has focused on WNV, but more recent studies have investigated POWV pathogenesis in mice; these studies have studied POWV disease using laboratory mouse lines such as C57BL/6J and Balb/c, as well as *Peromyscus* mice which are thought to serve as reservoirs for Lineage II POWV (DTV) in nature (53-57). C57BL/6J mice are highly susceptible to POWV, which makes them useful for modeling severe human disease, but makes them less useful for defining the mechanisms that allow the majority of infected individuals to sustain mild or asymptomatic infections while a small subset of infected individuals develop severe neuroinvasive disease. Comparing POWV infection in resistant CC lines (e.g., CC045) to susceptible lines (e.g., CC071) has the potential to reveal which aspects of POWV infection and the resulting host immune response (e.g., viral loads in the periphery, persistent viremia, neuroinvasion, replication within the CNS, damage to CNS neurons, neuroinflammation, etc.) correlate with severe

neurologic disease. CC mice can be useful models of relevant disease presentations that are not evident in conventional laboratory mouse lines, such as encephalitis caused by Rift Valley fever virus (34) or chronic WNV disease (58).

Altogether, our results support a model in which CC045 mice are resistant to severe POWV disease due to reduced viral replication in myeloid cells and rapid clearance of viremia, reducing the probability of neuroinvasion, and that this resistance is independent of a role for *Oas1b* in restricting flavivirus pathogenesis. This model suggests that the resistance mechanism of CC045 mice acts in peripheral tissues, not within the CNS. Although the mechanisms by which flaviviruses cross the blood-brain barrier and invade the CNS remain incompletely understood (59), hematogenous neuroinvasion likely is somewhat stochastic and prolonged high viremia (e.g., in CC071 mice) increases the probability of virus crossing the BBB. We expect that once any POWV accesses the CNS it encounters a highly permissive and sensitive environment, resulting in uniform lethality. Accordingly, while we detected no virus in the brains of most CC045 mice, 2 of 6 CC045 mice did have virus in their brains and at levels equivalent to CC071 mice, consistent with the ~22% lethality we observed for CC045 mice. The model that CC045 resistance results from rapid clearance of viremia is somewhat at odds with the observation that susceptibility did not correlate with 2 dpi viremia either within or among CC lines. However, this model is supported by the distinct viremia kinetics between CC045 and CC071 mice and suggests that rapid clearance, but not peak viremia, is a key determinant of POWV susceptibility in CC mice. Future studies will characterize viral replication in cell types other than macrophages and will compare CNS immune infiltrates

and CNS pathology in CC045 mice versus CC071 to determine whether these lines differ in BBB permeability at baseline and in response to POWV infection.

In general, the susceptibility phenotypes we observed were concordant among the neuroinvasive viruses tested, suggesting that CC045 resistance likely results from a pan-flavivirus mechanism. However, we found that CC006 mice were highly susceptible to WNV and POWV but relatively resistant to JEV. Future studies will investigate the mechanism of JEV resistance in CC006 mice, potentially revealing disease mechanisms that are specific to JEV compared to other flaviviruses.

Host genes related to the antiviral immune response have been associated with the outcome of flavivirus infection in humans (16). For example, a common polymorphism that ablates expression of the chemokine receptor CCR5 (CCR5 Δ 32, best characterized because homozygotes are protected against HIV infection because CCR5 is the main co-receptor for HIV entry (60)) is associated with higher risk of WNV and TBEV symptomatic presentation and neuroinvasive disease (10, 14, 17, 18). A protective role for CCR5 against WNV and TBEV disease is consistent with studies showing that CCR5 deficient mice exhibit impaired trafficking of CD8 T cells necessary to clear flavivirus CNS infection (61-64). Furthermore, polymorphisms in the dsRNA sensors OAS1, OAS2, and OAS3 are associated with WNV and TBEV infection and neuroinvasive disease (10, 65, 66). Mechanistically, the SNP rs10774671 of OAS1 corresponds to a A>G change in a splice acceptor site, where the G allele (protective) generates the p46 isoform of OAS1. The p46 isoform is prenylated, localizes to flavivirus replication complexes on ER membranes, and inhibits WNV replication, whereas the p42 isoform (resulting from the A allele) is not prenylated and lacks antiviral activity (67). Among the 8 murine orthologs of OAS1, Oas1b

and Oas1g both encode a C-terminal CaaX domain homologous to the prenylation site in the p46 isoform of human OAS1 (67). But whereas Oas1b plays a dominant role restricting flavivirus pathogenesis in mice, we found no effect of Oas1g on survival after WNV or POWV infection. This could indicate that Oas1g is not important for controlling flavivirus infection, that the antiviral effects of Oas1g are not strong enough to affect lethality, or that the antiviral effects of Oas1g are not evident on the *Oas1b*^{null} C57BL/6J genetic background.

Polymorphisms within additional antiviral response genes (e.g., CD209/DC-SIGN, TLR3, IL-10) are associated with TBEV infection (11-15). Similarly, polymorphisms within antiviral response genes such as HERC5, IRF3, and MX1 are associated with WNV infection (10, 16, 68, 69). Other polymorphic host genes play a role in flavivirus infection, although their effect on human disease is less clear. TMEM41B is an ER-associated lipid scramblase that promotes replication of a wide variety of flaviviruses (including POWV, TBEV, and WNV) (70). TMEM41B is polymorphic in humans and TMEM41B alleles vary in their ability to support flavivirus replication in cell culture (70), although associations with the risk or outcome of flavivirus infection remain to be demonstrated.

Extensive studies using transgenic knockout mice have revealed the effects of various innate and adaptive immune genes on the pathogenesis of WNV and other flaviviruses (71) but investigating flavivirus pathogenesis in CC mice allows us to study complex traits and polymorphic alleles that better recapitulate the genetic diversity found in human populations (30, 33). A limitation of CC studies is that they can only reveal genetic factors that are polymorphic among the 8 CC founder lines (or private mutations that arose during the breeding of CC lines). Future studies will use F2 crosses of resistant

(e.g., CC045) and susceptible (e.g., CC071) CC lines and genetic mapping approaches to define the host genetic factors that contribute to the resistant phenotype of CC045 mice, analogous to previous studies that have used similar approaches to map QTL and underlying causal genes that contribute to host control of influenza A virus, SARS-CoV, SARS-CoV-2, and WNV (35, 37, 72-74).

Previous studies have used CC mice to investigate host genetic factors controlling WNV infection and pathogenesis (36, 37, 58, 75-77). These studies used F1 crosses of CC parental lines, so it is not straightforward to draw comparisons with the phenotypes we identified in CC parental lines. Further, our key lines of interest, CC045 and CC071, were not included in the earlier WNV studies. However, the QTL with the largest effect size identified in these studies mapped to *Oas1b* (36, 37). With this in mind, we designed our experiments to use only *Oas1b*^{null} CC lines, allowing us to identify other polymorphic genes that contribute to disease outcome. However, our design does not detect factors that are dependent upon or synergize with *Oas1b* for their activity. Since we expected *Oas1b*^{null} mice to be susceptible to neuroinvasive flaviviruses, the remarkable finding in our study was that CC045 mice were resistant to diverse neuroinvasive flaviviruses, even in the absence of *Oas1b*. We also identified other *Oas1b*^{null} CC lines (such as CC057) with more modest resistance phenotypes; future studies will investigate whether the resistant phenotype of CC057 mice derives from the same mechanism as CC045 mice. Notably, CC057 mice also were relatively resistant to RVFV, exhibiting a delayed disease course resulting in encephalitis rather than acute hepatitis (34). CC071 mice, which we identified as being highly susceptible to POWV, WNV, JEV, and SLEV previously have been found to be highly susceptible to SARS-CoV-2 (78) and RVFV (34) and were highly

susceptible to ZIKV when treated with an IFNAR1-blocking antibody (79). Altogether this suggests that CC mice can reveal immune mechanisms that control pathogenesis of diverse viruses.

In this study, we demonstrated that *Oas1b* restricts POWV pathogenesis, which was not surprising given that *Oas1b* has been shown to restrict all flaviviruses tested to date. Despite observing marked differences in survival between CC019-*Oas1b*^{del} and CC019 mice, we found no significant difference in WNV or POWV replication in CC019-*Oas1b*^{del} MEFs compared to CC019 MEFs, even though *Oas1b* has been shown to restrict flavivirus replication in MEFs derived from C3H.PRI-Flv^r mice (80). This discordance could be due to distinct genetic features of CC019 mice and differences between MEFs and other cell types. In this study, we also demonstrated the ability to generate genetic knockouts on a CC background (CC019-*Oas1b*^{del}), which will enable the study of the function of single genes in the context of genetically diverse mouse models.

Prevention of neuroinvasion could be achieved by one or more mechanisms, including a tighter BBB, modulated leukocyte trafficking into the CNS, and enhanced clearance of virus from the periphery. The data from the present study support a model of POWV pathogenesis in which persistent high levels of viremia increases the likelihood of virus stochastically breaching the BBB and accessing the CNS, where it leads to mortality. Thus, we propose that CC045 mice resist POWV infection by promoting the rapid clearance of POWV from the circulation and therefore limiting the opportunity for POWV neuroinvasion, and this effect is mediated by host factors outside of *Oas1b*. Future studies will investigate these non-*Oas1b* host factors using an F2 cross of susceptible

and resistant CC mice and use quantitative genetics approaches to identify polymorphic genes that contribute to the resistant phenotype of CC045 mice.

MATERIALS AND METHODS

Cells and viruses. Vero (African green monkey kidney epithelial) cells were maintained in Dulbecco's modified Eagle medium (DMEM) containing 5% heat-inactivated FBS at 37°C with 5% CO₂. POWV strains LB (Lineage I) and Spooner (DTV, Lineage II), WNV strain NY2000, JEV strain Nakayama, and SLEV strain GHA-3 were provided by Dr. Michael Diamond (Washington University in St. Louis). POWV strain MB5/12 (DTV, Lineage II) was provided by Dr. Greg Ebel (Colorado State University). All viruses were handled under BSL3 containment. Virus stocks were grown in Vero cells and titered by focus-forming assay (FFA) (81). Duplicates of serial 10-fold dilutions of virus in growth medium (DMEM containing 2% FBS and 20 mM HEPES) were applied to Vero cells in 96-well plates and incubated at 37°C with 5% CO₂. After 1 hour, cells were overlaid with 1% methylcellulose in minimum essential medium Eagle (MEM) containing 2% heat-inactivated fetal bovine serum (FBS). Following incubation for approximately 24 hours (WNV), 24-36 hours (JEV), or 48 hours (POWV and SLEV), plates were fixed with 2% paraformaldehyde for 2 hours at room temperature. Fixed plates were incubated with 500 ng/ml flavivirus cross-reactive mouse MAbs ZV13 (82) or E60 (83) for 2 hr at room temperature or overnight at 4°C. After incubation at room temperature for 1 hr with a 1:2,500 dilution of horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG

(Sigma), foci were detected by addition of TrueBlue substrate (KPL). Foci were quantified with a CTL Immunospot instrument.

Mice. All mouse procedures were performed under protocols approved by the Institutional Animal Care and Use Committee at the University of North Carolina at Chapel Hill. CC mice were obtained from the UNC Systems Genetics Core Facility directly or as breeder pairs that were mated in-house. C57BL/6J mice were bred in-house. *Oas1g^{-/-}* mice were obtained from Dr. Timothy Sheahan (UNC). All mouse work was performed under ABSL3 containment. Five-week-old or 9 to 12-week-old mice male and female mice were inoculated in a volume of 50 μ l by a subcutaneous (footpad) route. Mice received 100 FFU of POWV strain LB, MB5/12, or Spooner (DTV), WNV strain NY2000, JEV strain Nakayama or SLEV strain GHA-3, diluted in HBSS with Ca²⁺ and Mg²⁺ supplemented with 1% heat-inactivated FBS. Mice were monitored daily for disease signs for 21 days or until the time of tissue harvest. Mice were euthanized upon reaching humane endpoints including loss of \geq 20% of starting weight, non-responsiveness, or severe neurological disease signs (hunching, paralysis) interfering with the ability to access food and water; euthanized mice were scored as dead the following day. To evaluate viremia, blood was collected 2 dpi by submandibular bleed with a 5mm Goldenrod lancet, or by cardiac puncture prior to perfusion in tissue harvest experiments.

Generation of CC019-*Oas1b*^{del} mice. CC019-*Oas1b*^{del} mice were generated through the UNC Mutant Mouse Resource and Research Center, as part of a project to demonstrate the feasibility of performing CRISPR/Cas9 genome editing in CC mice. The CC019 line

was chosen because it contains a functional *Oas1b* allele (derived from the WSB founder) and exhibited robust superovulation and in vitro fertilization (IVF) performance, with egg yields and embryo progression to the two-cell stage comparable to C57BL/6J mice. 4 CRISPR guide RNAs targeting the SNP position of the WSB allele were designed and validated. Two guide RNAs showed full activity *in vitro* and were chosen for microinjection. A donor oligonucleotide was designed to introduce the susceptible SNP plus additional silent mutations to disrupt Cas9 binding and cleavage of the introduced allele and to facilitate genotyping of the resulting animals. Microinjection conditions: Cas9 mRNA (20 or 40 ng/μl), 1 guide RNA (10 or 20 ng/μl) and donor oligonucleotide (20 or 50 ng/μl) were co-injected into the pronucleus of one-cell embryos produced by IVF. IVF/microinjection was performed for 3 days. The CC019 strain responded moderately to superovulation (average 8.3 eggs/female). IVF was successful on each of the 3 days, yielding a total of 358 injectable embryos (6.2/female). Injection survival and progression to the two-cell stage in vitro were comparable to C57BL/6J. However, production of live pups from injected embryos was low: only 2 live pups were produced from 280 implanted embryos. Both pups had CRISPR-induced mutations at the *Oas1b* locus. CC019-*Oas1b*^{del} mice are homozygous for a 12 base pair deletion in exon 4 of *Oas1b* which generates an in-frame 4 amino acid deletion. CC019-*Oas1b*^{del} mice were bred as knockout x knockout and exhibited similar breeding performance as the parental CC019 line. CC019-*Oas1b*^{del} mice were genotyped by generating a PCR amplicon from tail snip DNA using forward primer CCACACACAACCACCAGGAACC and reverse primer GGCTGTAGGACCTCATGTCAATCA, then sequencing with the forward primer TCTCATTGCCTTTCTCTTCTCAGTGTA. The wild-type sequence is

GGGAGTATGGGAGTCCGAGTAACTAAATTCAACACAGCCCAGGGCTTCCGAACCG
TCTTGGAAGTGGTCACCAAGTACAAACAGCTTCGAATCTACTGGACAGTGTATTAT
GACTTTTCGACATCAAGAGGTCTCTGAATACCTGCACCAA and the *Oas1b*^{del} sequence
is
GGGAGTATGGGAGTCCGAGTAACTAAATTCAACACAGCCCAGGACTTGGAAGTGG
TCACCAAGTACAAACAGCTTCGAATCTACTGGACAGTGTATTATGACTTTTCGACATC
AAGAGGTCTCTGAATACCTGCACCAA.

Mouse Embryo Fibroblasts. Mouse embryo fibroblasts (MEFs) were prepared from E15 embryos. Pregnant mice were euthanized and the gravid uterus was isolated. Embryos were removed, placed in PBS, decapitated, and gut and liver were removed. Embryos were then minced with scalpels, trypsinized (1 ml per embryo), pipetted up and down with a 10 ml serological pipette to break up any chunks, and incubated for 5-10 min at room temperature. Cells were resuspended in DMEM supplemented with non-essential amino acids, L-Glutamine, Pen/Strep, and 10% heat-inactivated FBS and then pelleted by centrifugation at 1000 rpm for 5 min at 4°C. Supernatants were removed and cell pellets were resuspended in fresh media and pelleted again by centrifugation at 1000 rpm for 5 min at 4°C. Cell pellets were resuspended in 1 ml per embryo of fresh media and plated into culture flasks (1.5 embryos per T-150 flask) in 25 ml of fresh media and incubated at 37°C with 5% CO₂. After 24 hours, media was removed, cells were washed with 1X PBS, and fresh media was added. When monolayers reached near-confluency, MEFs were frozen down in DMEM supplemented with non-essential amino acids, L-Glutamine, Pen/Strep, 30% heat-inactivated FBS, and 20% DMSO and stored in liquid nitrogen.

Thawed MEFs were seeded in 6-well plates at 2×10^5 cells per well in DMEM supplemented with non-essential amino acids, L-Glutamine, Pen/Strep, and 10% heat-inactivated FBS. MEFs were infected at an MOI of 0.01 with POWV strain LB or WNV strain NY2000. After 1 hour, inoculum was removed and replaced with fresh media and plates were incubated at 37°C with 5% CO₂. After 4, 24, 48, or 72 hours, supernatants were collected and titered by focus-forming assay on Vero cells.

Bone-marrow derived macrophages. Bone marrow-derived macrophages (BMDM) were generated from CC mice. Mice were euthanized and femurs and tibias were isolated from hind limbs. Bone marrow was flushed out with 10 ml DMEM delivered via syringe with 25G ½ inch needle. Bone marrow was pooled and pipetted up and down with a 5 ml serological pipette to break up large chunks. Cells were pelleted by centrifugation at 1500 rpm for 5 min at 4°C. Supernatants were removed and cell pellets were resuspended in ACK Red Blood Cell Lysis Buffer containing 150 mM NH₄Cl, 10 mM KHCO₃, and 0.1 mM EDTA pH 7.3, and incubated for 2-3 minutes. Cells were resuspended in DMEM containing 10% heat-inactivated FBS and then pelleted by centrifugation at 1500 rpm for 5 min at 4°C. Cell pellets were resuspended in DMEM containing 10% heat-inactivated FBS and counted. 12-well non-TC treated plates were seeded with 1.5×10^5 cells/well in 1 ml of DMEM containing L-Glutamine, NaPyr, Pen/Strep, 10% heat-inactivated FBS, and 40 ng/ml mouse M-CSF (BioLegend 576406) and incubated for 7 days at 37°C with 5% CO₂. BMDMs were infected at an MOI of 0.01 with POWV strain MB5/12 or WNV strain NY2000 in DMEM containing L-Glutamine, NaPyr, Pen/Strep, 10% heat-inactivated FBS, and 20 ng/ml mouse M-CSF. After 1 hour, inoculum was removed and replaced with fresh

media and plates were incubated at 37°C with 5% CO₂. After 4, 24, 48, or 72 hours, supernatants were collected and titered by focus-forming assay on Vero cells.

Measurement of Viremia. Blood was collected from mice by submandibular bleed or terminal cardiac puncture in serum separator tubes (BD). Serum was separated by centrifugation for 8000 rpm for 4 min and stored at -80°C until RNA isolation. RNA was extracted with the Viral RNA Mini Kit (Qiagen). Viral RNA levels were determined by TaqMan one-step qRT-PCR on a CFX96 Touch Real-Time PCR Detection System (BioRad) using standard cycling conditions. Viremia is expressed on a Log₁₀ scale as copies per ml based on a standard curve produced using serial 10-fold dilutions of a DNA plasmid containing a 400 bp gBlock (Integrated DNA Technologies) encoding a portion of the viral envelope (E) protein sequence. All primers and probes were purchased from Integrated DNA Technologies. Primers used to detect POWV MB5/12 were: forward, GAAGCTGAAAGGCACAACCTTAC; reverse, CACCTCCATGACCACTGTATC; and probe, AAGAGTTCCTGTGGACAGTGGTCA. Primers used to detect WNV NY2000 were: forward, TCAGCGATCTCTCCACCAAAG; reverse, GGGTCAGCACGTTTGTTCATTG; and probe, TGCCCGACCATGGGAGAAGCTC. Primers used to detect JEV Nakayama were: forward, CAGCGTGGAGAAACAGAGAA; reverse, TGTGACCCAAGAGCAACAA; and probe, CATGGAATTTGAAGAGGCGCACGC.

Tissue Titers. Nine to twelve-week-old male and female mice were infected with 100 FFU of POWV strain MB5/12. At 3 or 7 dpi, mice were bled by cardiac puncture, perfused

with 20 ml of PBS, and tissues were harvested. Brains and spleens were collected into 2 ml screwcap tubes containing 1 ml of DMEM supplemented with 2% heat-inactivated FBS and homogenizer beads. Tissues were stored at -80°C until processing. Tissues were thawed and homogenized using a MagNA Lyser (Roche) set to 6000 for 1 min. Homogenates were titered by plaque assay on Vero cells. Serial 10-fold dilutions of tissue homogenates were applied to Vero cells in 6-well plates and incubated at 37°C with 5% CO₂. After 1 hour, cells were overlaid with 1% methylcellulose in minimum essential medium Eagle (MEM) containing 2% heat-inactivated FBS. Following incubation for 6 days, plates were fixed with 2% paraformaldehyde overnight at room temperature. Fixed plates were stained with 1% crystal violet in 20% ethanol, washed with tap water, and plaques were counted manually.

Data analysis. Data were analyzed with GraphPad Prism software. Growth curves were analyzed by two-way ANOVA to assess the impact of time and CC line on viral replication, compared to CC019-*Oas1b*^{del} (Fig. 1E-F) or CC045 (Fig. 5). Viremia was compared to CC045 mice by one-way ANOVA (Fig. 4). Tissue titers were analyzed by two-way ANOVA to assess the impact of time and CC line on viral loads, compared to CC045 (Fig. 6). A p value of < 0.05 was considered statistically significant.

ACKNOWLEDGEMENTS

This work was supported by R21 AI145377 (H.M.L.), R01 AI170625 (H.M.L.), and U19 AI100625 (M.T.H. and M.T.F.), by start-up funds from the UNC Lineberger Comprehensive Cancer Center and Department of Microbiology & Immunology, and by

Systems Genetics Pilot Projects from the UNC School of Medicine. B.A.J. was supported by F32 AI61786. K.E.N. was supported by T32 AI007419. We appreciate the support of the Systems Genetics Core Facility and Mutant Mouse Research and Resource Center and we also acknowledge Dr. Dale Cowley and the UNC Animal Models Core Facility for generating the CC019-*Oas1b*^{del} mice.

REFERENCES

1. Gould EA, Solomon T. 2008. Pathogenic flaviviruses. *Lancet* 371:500-9.
2. Solomon T. 2004. Flavivirus encephalitis. *N Engl J Med* 351:370-8.
3. Hermance ME, Thangamani S. 2017. Powassan Virus: An Emerging Arbovirus of Public Health Concern in North America. *Vector Borne Zoonotic Dis* 17:453-462.
4. Paules CI, Marston HD, Bloom ME, Fauci AS. 2018. Tickborne Diseases - Confronting a Growing Threat. *N Engl J Med* 379:701-703.
5. McLean DM, Donohue WL. 1959. Powassan virus: isolation of virus from a fatal case of encephalitis. *Can Med Assoc J* 80:708-11.
6. Beasley DW, Suderman MT, Holbrook MR, Barrett AD. 2001. Nucleotide sequencing and serological evidence that the recently recognized deer tick virus is a genotype of Powassan virus. *Virus Res* 79:81-9.
7. Kuno G, Artsob H, Karabatsos N, Tsuchiya KR, Chang GJ. 2001. Genomic sequencing of deer tick virus and phylogeny of powassan-related viruses of North America. *Am J Trop Med Hyg* 65:671-6.
8. Ebel GD, Spielman A, Telford SR. 2001. Phylogeny of North American Powassan virus. *J Gen Virol* 82:1657-1665.
9. Ebel GD. 2010. Update on Powassan virus: emergence of a North American tick-borne flavivirus. *Annu Rev Entomol* 55:95-110.
10. Bigham AW, Buckingham KJ, Husain S, Emond MJ, Bofferding KM, Gildersleeve H, Rutherford A, Astakhova NM, Perelygin AA, Busch MP, Murray KO, Sejvar JJ, Green S, Kriesel J, Brinton MA, Bamshad M. 2011. Host genetic risk factors for West Nile virus infection and disease progression. *PLoS One* 6:e24745.
11. Barkhash AV, Babenko VN, Voevoda MI, Romaschenko AG. 2016. Association of IL28B and IL10 gene polymorphism with predisposition to tick-borne encephalitis in a Russian population. *Ticks Tick Borne Dis* 7:808-812.
12. Barkhash AV, Perelygin AA, Babenko VN, Brinton MA, Voevoda MI. 2012. Single nucleotide polymorphism in the promoter region of the CD209 gene is associated with human predisposition to severe forms of tick-borne encephalitis. *Antiviral Res* 93:64-8.
13. Barkhash AV, Voevoda MI, Romaschenko AG. 2013. Association of single nucleotide polymorphism rs3775291 in the coding region of the TLR3 gene with predisposition to tick-borne encephalitis in a Russian population. *Antiviral Res* 99:136-8.

14. Kindberg E, Mickiene A, Ax C, Akerlind B, Vene S, Lindquist L, Lundkvist A, Svensson L. 2008. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. *J Infect Dis* 197:266-9.
15. Mickiene A, Pakalniene J, Nordgren J, Carlsson B, Hagbom M, Svensson L, Lindquist L. 2014. Polymorphisms in chemokine receptor 5 and Toll-like receptor 3 genes are risk factors for clinical tick-borne encephalitis in the Lithuanian population. *PLoS One* 9:e106798.
16. Cahill ME, Conley S, DeWan AT, Montgomery RR. 2018. Identification of genetic variants associated with dengue or West Nile virus disease: a systematic review and meta-analysis. *BMC Infect Dis* 18:282.
17. Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, Cheshier RC, Murphy PM. 2006. CCR5 deficiency increases risk of symptomatic West Nile virus infection. *J Exp Med* 203:35-40.
18. Lim JK, McDermott DH, Lisco A, Foster GA, Krysztof D, Follmann D, Stramer SL, Murphy PM. 2010. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. *J Infect Dis* 201:178-85.
19. Webster LT. 1937. Inheritance of Resistance of Mice to Enteric Bacterial and Neurotropic Virus Infections. *J Exp Med* 65:261-86.
20. Pereygin AA, Scherbik SV, Zhulin IB, Stockman BM, Li Y, Brinton MA. 2002. Positional cloning of the murine flavivirus resistance gene. *Proc Natl Acad Sci U S A* 99:9322-7.
21. Mashimo T, Lucas M, Simon-Chazottes D, Frenkiel MP, Montagutelli X, Ceccaldi PE, Deubel V, Guenet JL, Despres P. 2002. A nonsense mutation in the gene encoding 2'-5'-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. *Proc Natl Acad Sci U S A* 99:11311-6.
22. Webster LT. 1933. Inherited and Acquired Factors in Resistance to Infection : I. Development of Resistant and Susceptible Lines of Mice through Selective Breeding. *J Exp Med* 57:793-817.
23. Casals J, Schneider HA. 1943. Natural Resistance and Susceptibility to Russian Spring-Summer Encephalitis in Mice. *Proceedings of the Society for Experimental Biology and Medicine* 54:201-202.
24. Webster LT, Clow AD. 1936. Experimental Encephalitis (St. Louis Type) in Mice with High Inborn Resistance : A Chronic Subclinical Infection. *J Exp Med* 63:827-45.
25. Webster LT, Johnson MS. 1941. Comparative Virulence of St. Louis Encephalitis Virus Cultured with Brain Tissue from Innately Susceptible and Innately Resistant Mice. *J Exp Med* 74:489-94.
26. Sawyer WA, Lloyd W. 1931. The Use of Mice in Tests of Immunity against Yellow Fever. *J Exp Med* 54:533-55.
27. Lynch CJ, Hughes TP. 1936. The Inheritance of Susceptibility to Yellow Fever Encephalitis in Mice. *Genetics* 21:104-12.
28. Brinton MA, Pereygin AA. 2003. Genetic resistance to flaviviruses. *Adv Virus Res* 60:43-85.
29. Collaborative Cross C. 2012. The genome architecture of the Collaborative Cross mouse genetic reference population. *Genetics* 190:389-401.

30. Noll KE, Ferris MT, Heise MT. 2019. The Collaborative Cross: A Systems Genetics Resource for Studying Host-Pathogen Interactions. *Cell Host Microbe* 25:484-498.
31. Srivastava A, Morgan AP, Najarian ML, Sarsani VK, Sigmon JS, Shorter JR, Kashfeen A, McMullan RC, Williams LH, Giusti-Rodriguez P, Ferris MT, Sullivan P, Hock P, Miller DR, Bell TA, McMillan L, Churchill GA, de Villena FP. 2017. Genomes of the Mouse Collaborative Cross. *Genetics* 206:537-556.
32. Graham JB, Swarts JL, Mooney M, Choonoo G, Jeng S, Miller DR, Ferris MT, McWeeney S, Lund JM. 2017. Extensive Homeostatic T Cell Phenotypic Variation within the Collaborative Cross. *Cell Rep* 21:2313-2325.
33. Leist SR, Baric RS. 2018. Giving the Genes a Shuffle: Using Natural Variation to Understand Host Genetic Contributions to Viral Infections. *Trends Genet* 34:777-789.
34. Cartwright HN, Barbeau DJ, Doyle JD, Klein E, Heise MT, Ferris MT, McElroy AK. 2022. Genetic diversity of collaborative cross mice enables identification of novel rift valley fever virus encephalitis model. *PLoS Pathog* 18:e1010649.
35. Schafer A, Leist SR, Gralinski LE, Martinez DR, Winkler ES, Okuda K, Hawkins PE, Gully KL, Graham RL, Scobey DT, Bell TA, Hock P, Shaw GD, Loomer JF, Madden EA, Anderson E, Baxter VK, Taft-Benz SA, Zweigart MR, May SR, Dong S, Clark M, Miller DR, Lynch RM, Heise MT, Tisch R, Boucher RC, Pardo Manuel de Villena F, Montgomery SA, Diamond MS, Ferris MT, Baric RS. 2022. A Multitrait Locus Regulates Sarbecovirus Pathogenesis. *mBio* 13:e0145422.
36. Graham JB, Thomas S, Swarts J, McMillan AA, Ferris MT, Suthar MS, Treuting PM, Ireton R, Gale M, Jr., Lund JM. 2015. Genetic diversity in the collaborative cross model recapitulates human West Nile virus disease outcomes. *mBio* 6:e00493-15.
37. Green R, Wilkins C, Thomas S, Sekine A, Hendrick DM, Voss K, Ireton RC, Mooney M, Go JT, Choonoo G, Jeng S, de Villena FP, Ferris MT, McWeeney S, Gale M, Jr. 2017. Oas1b-dependent Immune Transcriptional Profiles of West Nile Virus Infection in the Collaborative Cross. *G3 (Bethesda)* 7:1665-1682.
38. Elbahesh H, Jha BK, Silverman RH, Scherbik SV, Brinton MA. 2011. The Flvr-encoded murine oligoadenylate synthetase 1b (Oas1b) suppresses 2-5A synthesis in intact cells. *Virology* 409:262-70.
39. Kakuta S, Shibata S, Iwakura Y. 2002. Genomic structure of the mouse 2',5'-oligoadenylate synthetase gene family. *J Interferon Cytokine Res* 22:981-93.
40. Kemenesi G, Banyai K. 2019. Tick-Borne Flaviviruses, with a Focus on Powassan Virus. *Clin Microbiol Rev* 32.
41. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, Ginsburg AS. 2011. Estimated global incidence of Japanese encephalitis: a systematic review. *Bull World Health Organ* 89:766-74, 774A-774E.
42. Heffelfinger JD, Li X, Batmunkh N, Grabovac V, Diorditsa S, Liyanage JB, Pattamadilok S, Bahl S, Vannice KS, Hyde TB, Chu SY, Fox KK, Hills SL, Marfin AA. 2017. Japanese Encephalitis Surveillance and Immunization - Asia and Western Pacific Regions, 2016. *MMWR Morb Mortal Wkly Rep* 66:579-583.

43. Furuya-Kanamori L, Gyawali N, Mills DJ, Hugo LE, Devine GJ, Lau CL. 2022. The Emergence of Japanese Encephalitis in Australia and the Implications for a Vaccination Strategy. *Trop Med Infect Dis* 7.
44. Centers for Disease Control and Prevention. West Nile Virus: Final Cumulative Maps & Data for 1999– 2020 [updated December 17, 2021]. <https://www.cdc.gov/westnile/statsmaps/cumMapsData.html>. Accessed
45. Lindquist L, Vapalahti O. 2008. Tick-borne encephalitis. *Lancet* 371:1861-71.
46. Heinz FX, Stiasny K, Holzmann H, Grgic-Vitek M, Kriz B, Essl A, Kundi M. 2013. Vaccination and tick-borne encephalitis, central Europe. *Emerg Infect Dis* 19:69-76.
47. Roesch F, Fajardo A, Moratorio G, Vignuzzi M. 2019. Usutu Virus: An Arbovirus on the Rise. *Viruses* 11.
48. Cle M, Beck C, Salinas S, Lecollinet S, Gutierrez S, Van de Perre P, Baldet T, Foulongne V, Simonin Y. 2019. Usutu virus: A new threat? *Epidemiol Infect* 147:e232.
49. Shives KD, Tyler KL, Beckham JD. 2017. Molecular mechanisms of neuroinflammation and injury during acute viral encephalitis. *J Neuroimmunol* 308:102-111.
50. Milora KA, Rall GF. 2019. Interferon Control of Neurotropic Viral Infections. *Trends Immunol* 40:842-856.
51. Klein RS, Hunter CA. 2017. Protective and Pathological Immunity during Central Nervous System Infections. *Immunity* 46:891-909.
52. Klein RS, Garber C, Howard N. 2017. Infectious immunity in the central nervous system and brain function. *Nat Immunol* 18:132-141.
53. Stone ET, Hassert M, Geerling E, Wagner C, Brien JD, Ebel GD, Hirsch AJ, German C, Smith JL, Pinto AK. 2022. Balanced T and B cell responses are required for immune protection against Powassan virus in virus-like particle vaccination. *Cell Rep* 38:110388.
54. Santos RI, Hermance ME, Reynolds ES, Thangamani S. 2021. Salivary gland extract from the deer tick, *Ixodes scapularis*, facilitates neuroinvasion by Powassan virus in BALB/c mice. *Sci Rep* 11:20873.
55. Mlera L, Meade-White K, Saturday G, Scott D, Bloom ME. 2017. Modeling Powassan virus infection in *Peromyscus leucopus*, a natural host. *PLoS Negl Trop Dis* 11:e0005346.
56. Hermance ME, Thangamani S. 2015. Tick Saliva Enhances Powassan Virus Transmission to the Host, Influencing Its Dissemination and the Course of Disease. *J Virol* 89:7852-60.
57. Pesko KN, Torres-Perez F, Hjelle BL, Ebel GD. 2010. Molecular epidemiology of Powassan virus in North America. *J Gen Virol* 91:2698-705.
58. Graham JB, Swarts JL, Wilkins C, Thomas S, Green R, Sekine A, Voss KM, Ireton RC, Mooney M, Choonoo G, Miller DR, Treuting PM, Pardo Manuel de Villena F, Ferris MT, McWeeney S, Gale M, Jr., Lund JM. 2016. A Mouse Model of Chronic West Nile Virus Disease. *PLoS Pathog* 12:e1005996.
59. Cain MD, Salimi H, Diamond MS, Klein RS. 2019. Mechanisms of Pathogen Invasion into the Central Nervous System. *Neuron* 103:771-783.

60. Lopalco L. 2010. CCR5: From Natural Resistance to a New Anti-HIV Strategy. *Viruses* 2:574-600.
61. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM. 2005. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. *J Exp Med* 202:1087-98.
62. Larena M, Regner M, Lobigs M. 2012. The chemokine receptor CCR5, a therapeutic target for HIV/AIDS antagonists, is critical for recovery in a mouse model of Japanese encephalitis. *PLoS One* 7:e44834.
63. Durrant DM, Daniels BP, Pasieka T, Dorsey D, Klein RS. 2015. CCR5 limits cortical viral loads during West Nile virus infection of the central nervous system. *J Neuroinflammation* 12:233.
64. Michlmayr D, Bardina SV, Rodriguez CA, Pletnev AG, Lim JK. 2016. Dual Function of Ccr5 during Langat Virus Encephalitis: Reduction in Neutrophil-Mediated Central Nervous System Inflammation and Increase in T Cell-Mediated Viral Clearance. *J Immunol* 196:4622-31.
65. Lim JK, Lisco A, McDermott DH, Huynh L, Ward JM, Johnson B, Johnson H, Pape J, Foster GA, Krysztof D, Follmann D, Stramer SL, Margolis LB, Murphy PM. 2009. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. *PLoS Pathog* 5:e1000321.
66. Barkhash AV, Perelygin AA, Babenko VN, Myasnikova NG, Pilipenko PI, Romaschenko AG, Voevoda MI, Brinton MA. 2010. Variability in the 2'-5'-oligoadenylate synthetase gene cluster is associated with human predisposition to tick-borne encephalitis virus-induced disease. *J Infect Dis* 202:1813-8.
67. Soveg FW, Schwerk J, Gokhale NS, Cerosaletti K, Smith JR, Pairo-Castineira E, Kell AM, Forero A, Zaver SA, Esser-Nobis K, Roby JA, Hsiang TY, Ozarkar S, Clingan JM, McAnarney ET, Stone AE, Malhotra U, Speake C, Perez J, Balu C, Allenspach EJ, Hyde JL, Menachery VD, Sarkar SN, Woodward JJ, Stetson DB, Baillie JK, Buckner JH, Gale M, Jr., Savan R. 2021. Endomembrane targeting of human OAS1 p46 augments antiviral activity. *Elife* 10.
68. Danial-Farran N, Eghbaria S, Schwartz N, Kra-Oz Z, Bisharat N. 2015. Genetic variants associated with susceptibility of Ashkenazi Jews to West Nile virus infection. *Epidemiol Infect* 143:857-63.
69. Long D, Deng X, Singh P, Loeb M, Luring AS, Seielstad M. 2016. Identification of genetic variants associated with susceptibility to West Nile virus neuroinvasive disease. *Genes Immun* 17:298-304.
70. Hoffmann HH, Schneider WM, Rozen-Gagnon K, Miles LA, Schuster F, Razooky B, Jacobson E, Wu X, Yi S, Rudin CM, MacDonald MR, McMullan LK, Poirier JT, Rice CM. 2021. TMEM41B Is a Pan-flavivirus Host Factor. *Cell* 184:133-148 e20.
71. Manet C, Roth C, Tawfik A, Cantaert T, Sakuntabhai A, Montagutelli X. 2018. Host genetic control of mosquito-borne Flavivirus infections. *Mamm Genome* 29:384-407.
72. Ferris MT, Aylor DL, Bottomly D, Whitmore AC, Aicher LD, Bell TA, Bradel-Tretheway B, Bryan JT, Buus RJ, Gralinski LE, Haagmans BL, McMillan L, Miller DR, Rosenzweig E, Valdar W, Wang J, Churchill GA, Threadgill DW, McWeeney SK, Katze MG, Pardo-Manuel de Villena F, Baric RS, Heise MT. 2013. Modeling

- 838 host genetic regulation of influenza pathogenesis in the collaborative cross. *PLoS*
839 *Pathog* 9:e1003196.
- 840 73. Gralinski LE, Ferris MT, Aylor DL, Whitmore AC, Green R, Frieman MB, Deming
841 D, Menachery VD, Miller DR, Buus RJ, Bell TA, Churchill GA, Threadgill DW, Katze
842 MG, McMillan L, Valdar W, Heise MT, Pardo-Manuel de Villena F, Baric RS. 2015.
843 Genome Wide Identification of SARS-CoV Susceptibility Loci Using the
844 Collaborative Cross. *PLoS Genet* 11:e1005504.
- 845 74. Maurizio PL, Ferris MT, Keele GR, Miller DR, Shaw GD, Whitmore AC, West A,
846 Morrison CR, Noll KE, Plante KS, Cockrell AS, Threadgill DW, Pardo-Manuel de
847 Villena F, Baric RS, Heise MT, Valdar W. 2018. Bayesian Diallel Analysis Reveals
848 Mx1-Dependent and Mx1-Independent Effects on Response to Influenza A Virus
849 in Mice. *G3 (Bethesda)* 8:427-445.
- 850 75. Green R, Wilkins C, Thomas S, Sekine A, Ireton RC, Ferris MT, Hendrick DM,
851 Voss K, de Villena FP, Baric R, Heise M, Gale M, Jr. 2016. Identifying protective
852 host gene expression signatures within the spleen during West Nile virus infection
853 in the collaborative cross model. *Genom Data* 10:114-117.
- 854 76. Green R, Wilkins C, Thomas S, Sekine A, Ireton RC, Ferris MT, Hendrick DM,
855 Voss K, Pardo-Manuel de Villena F, Baric RS, Heise MT, Gale M, Jr. 2016.
856 Transcriptional profiles of WNV neurovirulence in a genetically diverse
857 Collaborative Cross population. *Genom Data* 10:137-140.
- 858 77. Graham JB, Swarts JL, Menachery VD, Gralinski LE, Schafer A, Plante KS,
859 Morrison CR, Voss KM, Green R, Choonoo G, Jeng S, Miller DR, Mooney MA,
860 McWeeney SK, Ferris MT, Pardo-Manuel de Villena F, Gale M, Heise MT, Baric
861 RS, Lund JM. 2020. Immune Predictors of Mortality After Ribonucleic Acid Virus
862 Infection. *J Infect Dis* 221:882-889.
- 863 78. Montagutelli X, Prot M, Jouvion G, Levillayer L, Conquet L, Reyes-Gomez E,
864 Donati F, Albert M, van der Werf S, Jaubert J, Simon-Lorière E. 2021. A mouse-
865 adapted SARS-CoV-2 strain replicating in standard laboratory mice. *bioRxiv*
866 doi:10.1101/2021.07.10.451880:2021.07.10.451880.
- 867 79. Manet C, Simon-Lorière E, Jouvion G, Hardy D, Prot M, Conquet L, Flamand M,
868 Panthier JJ, Sakuntabhai A, Montagutelli X. 2020. Genetic Diversity of
869 Collaborative Cross Mice Controls Viral Replication, Clinical Severity, and Brain
870 Pathology Induced by Zika Virus Infection, Independently of Oas1b. *J Virol* 94.
- 871 80. Scherbik SV, Paranjape JM, Stockman BM, Silverman RH, Brinton MA. 2006.
872 RNase L plays a role in the antiviral response to West Nile virus. *J Virol* 80:2987-
873 99.
- 874 81. Brien JD, Lazear HM, Diamond MS. 2013. Propagation, quantification, detection,
875 and storage of West Nile virus. *Curr Protoc Microbiol* 31:15D 3 1-15D 3 18.
- 876 82. Zhao H, Fernandez E, Dowd KA, Speer SD, Platt DJ, Gorman MJ, Govero J,
877 Nelson CA, Pierson TC, Diamond MS, Fremont DH. 2016. Structural Basis of Zika
878 Virus-Specific Antibody Protection. *Cell* 166:1016-1027.
- 879 83. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A,
880 Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS. 2006. Antibody
881 recognition and neutralization determinants on domains I and II of West Nile Virus
882 envelope protein. *J Virol* 80:12149-59.
- 883

FIGURE LEGENDS

Figure 1. *Oas1b* restricts pathogenesis of diverse neuroinvasive flaviviruses. A-D.

Five to six-week-old male and female CC019, CC019-*Oas1b*^{del}, or C57BL/6J mice were infected with 100 FFU of POWV strain LB (A), POWV DTV strain Spooner (B), WNV strain NY2000 (C), or JEV strain Nakayama (D) by subcutaneous inoculation in the footpad and lethality was monitored for 21 days. Data are combined from 4-5 experiments per virus. E-F. Mouse embryo fibroblasts (MEFs) were harvested from the indicated mouse lines for multistep growth curve analysis. MEFs were infected at an MOI of 0.01 with POWV strain LB (E) or WNV strain NY2000 (F). Supernatants were collected at 4, 24, 48, or 72 hours post-infection and titered by focus-forming assay on Vero cells. Results shown are the mean +/- SEM of 2-3 independent experiments performed in duplicate or triplicate. Asterisks represent statistical significance (* p<0.05, ** p<0.01, *** p<0.001) by two-way ANOVA compared to CC019-*Oas1b*^{del}. G-H. Nine to twelve-week-old C57BL/6J wild-type or *Oas1g*^{-/-} male and female mice were infected with 100 FFU of POWV strain MB5/12 (G) or WNV strain NY2000 (H) by subcutaneous inoculation in the footpad and lethality was monitored for 21 days.

Figure 2. Host factors influence POWV pathogenesis across *Oas1b*-null

Collaborative Cross mouse lines. Nine to twelve-week-old male and female mice were infected with 100 FFU of POWV (strain LB) by subcutaneous inoculation in the footpad and lethality was monitored for 21 days. Lines are ordered by percent survival and mean

time to death. N=34 C67BL/6 mice, 18 CC019-*Oas1b*^{del} mice, and 6-7 mice for other lines.

Data are combined from 9 experiments.

Figure 3. Susceptibility phenotypes in Collaborative Cross mice are shared among diverse neuroinvasive flaviviruses. A-D. Nine to twelve-week-old male and female mice from *Oas1b*-null CC lines were infected with 100 FFU of POWV strain MB5/12 (A), WNV strain NY2000 (B), JEV strain Nakayama (C), or SLEV strain GHA-3 (D) by subcutaneous inoculation in the footpad and lethality was monitored for 21 days. Data are combined from 4-8 experiments per virus. E. Nine to twelve-week-old male mice from *Oas1b*^{+/+} CC lines were infected with 100 FFU of POWV strain MB5/12 and lethality was monitored for 21 days. Data represent a single experiment.






















Figure 4. Serum viral loads at 2 dpi do not correlate with susceptibility to neuroinvasive flaviviruses. Nine to twelve-week-old male and female mice were infected with 100 FFU of POWV (A and B), WNV (C), or JEV (D) by subcutaneous inoculation in the footpad. Mice were bled 2 dpi and viremia was assessed by qRT-PCR. Asterisks represent statistical significance (* p<0.05, *** p<0.001) by one-way ANOVA compared to CC045 (panels A, C, and D). CC lines in A, C, and D are all *Oas1b*-null; CC lines in B are *Oas1b*^{+/+}. Open symbols denote surviving mice.

Figure 5. Susceptibility to flavivirus disease is concordant with restriction of viral replication in macrophages ex vivo. Bone marrow-derived macrophages (BMDM) were harvested from CC mice (CC045, CC071, and CC015) for multistep growth curve

analysis. BMDMs were infected at an MOI of 0.01 with POWV (A) or WNV (B). Supernatants were collected at 4, 24, 48, or 72 hours post-infection and titered by focus-forming assay on Vero cells. Results shown are the mean +/- SEM of 2-3 independent experiments performed in duplicate or triplicate. Asterisks represent statistical significance (* $p < 0.05$, *** $p < 0.001$) by two-way ANOVA compared to CC045.

Figure 6. Reduced CNS viral loads correlate with POWV resistance. Nine to twelve-week-old male and female CC071 (susceptible) and CC045 (resistant) mice were infected with 100 FFU of POWV (strain MB5/12) by subcutaneous inoculation in the footpad. A-D. At the indicated time points, mice were perfused and tissues were harvested. A. Mice were bled by cardiac puncture prior to perfusion and viremia was assessed by qRT-PCR. B-D. Spleen, brain, and spinal cord homogenates were titered by plaque assay on Vero cells. E-F. Mice were serially bled 2, 3, and 4 dpi and viremia was assessed by qRT-PCR. Asterisks represent statistical significance (* $p < 0.05$, *** $p < 0.001$) by two-way ANOVA.

Table 1: Collaborative Cross mouse lines used in this study.

| CC Line | Legend Symbol | <i>Oas1b</i> allele | POWV LB (Fig. 2) | | POWV MB5/12 (Fig. 3) | |
|------------------------------------|---|---------------------|------------------|------|----------------------|------|
| | | | % Lethality | MTD | % Lethality | MTD |
| CC001 |  | Null | 83 | 12.7 | - | - |
| CC003 |  | WSB | - | - | 0 | N/A |
| CC004 |  | PWK | - | - | 0 | N/A |
| CC006 |  | Null | 100 | 8.8 | 56 | 15.9 |
| CC013 |  | Null | 100 | 9.3 | - | - |
| CC015 |  | Null | 100 | 8.3 | 100 | 9.3 |
| CC016 |  | Null | 100 | 10.3 | - | - |
| CC019 |  | WSB | - | - | - | - |
| CC019- <i>Oas1b</i> ^{del} |  | Null | 78 | 12.9 | 38 | 16.5 |
| CC021 |  | Null | 100 | 9.2 | - | - |
| CC026 |  | Null | 100 | 9.5 | - | - |
| CC027 |  | Null | 83 | 10.8 | - | - |
| CC030 |  | WSB | - | - | 0 | N/A |
| CC043 |  | Null | 67 | 13.2 | - | - |
| CC045 |  | Null | 0 | N/A | 22 | 18.4 |
| CC049 |  | Null | 100 | 10.2 | - | - |
| CC051 |  | Null | 100 | 12.7 | - | - |
| CC057 |  | Null | 50 | 16.5 | 0 | N/A |
| CC061 |  | Null | 100 | 9.1 | - | - |
| CC062 |  | Null | 67 | 15.2 | - | - |
| CC071 |  | Null | 100 | 8.2 | 100 | 9.1 |

CC: Collaborative Cross

MTD: mean time to death (days)

-: not done

N/A: not applicable